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Stroke is the significant cause of human mortality and sufferings depending upon race
and demographic location. Melatonin is a potent antioxidant that exerts protective
effects in differential experimental stroke models. Several mechanisms have been
previously suggested for the neuroprotective effects of melatonin in ischemic brain
injury. The aim of this study is to investigate whether melatonin treatment affects
the glutamate N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4isoxazole propionic acid (AMPA) receptor signaling in cerebral cortex and striatum
24 h after permanent middle cerebral artery occlusion (MCAO). Melatonin (5 mg/kg)
attenuated ischemia-induced down regulation of NMDA receptor 2 (NR2a), postsynaptic
density-95 (PSD95) and increases NR2a/PSD95 complex association, which further
activates the pro-survival PI3K/Akt/GSK3β pathway with mitigated collapsin response
mediator protein 2 (CRMP2) phosphorylation. Furthermore, melatonin increases the
expression of γ-enolase, a neurotrophic factor in ischemic cortex and striatum, and
preserve the expression of presynaptic (synaptophysin and SNAP25) and postsynaptic
(p-GluR1845) protein. Our study demonstrated a novel neuroprotective mechanism for
melatonin in ischemic brain injury which could be a promising neuroprotective agent for
the treatment of ischemic stroke.
Keywords: melatonin, ischemic stroke, NMDA receptor, AMPA receptor, PI3K/AKT/GSK3 pathway

Abbreviations: BBB, blood brain barrier; BCA, bicinchoninic acid; BDP, break down products; CST, cell signaling
technology; DAB, 3, 30 -Diaminobenzidine tetra hydrochloride; Glu, glutamate; GSK-3β, glycogen synthase kinase-3β;
MCAO, middle cerebral artery occlusion; NMDAR, N-methyl-d-aspartate receptor; NO, nitric oxide; PVDF, poly-vinylidene
fluoride; SEM, standard error of mean; SNAP-25, synaptosomal associated protein 25; TBST, Tris-buffered saline containing
0.1% Tween-20; TdT, terminal deoxynucleotidyl transferase; TTC, quinone reductase 2 MT3, 2,3,5-triphenyltetrazolium
chloride; TUNEL, Terminal deoxynucleotidyl transferase dUTP nick end labeling.
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pathways have been proposed for melatonin, including the prosurvival PI3K/AKT, MAPK, oxidative stress related NRF2 and
Endothelin-1 (Andrabi et al., 2015). Recently we demonstrated
the multimechanistic way by which melatonin modulates the
expression of several proteins in ischemic brain (Shah et al.,
2018b). However, the exact mechanism linking these molecular
changes to excitotoxicity initiated by NMDAR remain unknown.
In this manuscript, we have examined the cascading molecular
changes downstream of NMDARs. Our results indicated that
melatonin may exert its protective effects by preventing
NR2a cleavage via promoting PSD95-NR2a interaction and by
increasing γ -enolase/PI3K/AKT/CRMP2 survival pathways.

INTRODUCTION
Stroke is the second leading cause of death worldwide. Around
5 million dies with another 5 million disabled permanently
each year (Goldberg, 2002). Thrombolytics, such as activase
and TNKase remained the few available pharmacological
choices for clinical application, and which is severely restricted
within 3–4.5 h of the onset of ischemia due to potential
side effects (Melandri et al., 2009). In the past decades,
extensive research work to unknot the complex mechanisms
of neuronal death after stroke revealed that Glu accumulation
results in the overload of calcium that mainly enter via
NMDAR ionotropic channels, eliciting NO activation induced
downstream signaling and neuronal death (Scannevin and
Huganir, 2000). Numerous NMDAR antagonists have been
developed that resulted in repetitive failures in clinical trials
(Lai et al., 2014). Further studies suggested that NMDAR
mediate contrasting effects depending on its localization, and
subunits constitution (Ikonomidou and Turski, 2002). NR2a
stimulation predominantly at the synapse induced pro-survival
signaling, while NR2b preferably at the extra synaptic areas
mediate the excitotoxic death pathways (Hardingham et al.,
2002; Liu et al., 2007). These results, although simply explained
the controversy, were later compromised by the ambiguous
effects of NR2b selective antagonist in clinical trials (Lai et al.,
2014). It is speculated that both subunits accounts for essential
glutamatergic signaling for physiological function, which severely
limit the feasibility of NMDAR antagonist as a therapeutic target
in ischemic stroke. Recent efforts have focused on promising
neuroprotective agents act downstream of NMDAR, which
impedes Glu-mediated neurotoxicity without compromising
glutamatergic neurotransmission (Tu et al., 2010).
Among various endogenous and synthetic neuroprotective
compounds such as estrogens and progesterone, melatonin is the
most extensively studied neuroprotective compound. Melatonin
is an indoleamine produced mainly in the pineal gland as well as
many other tissues such as retina, gut, and glia cell (Venegas et al.,
2012). It is especially effective as a powerful antioxidant, antiinflammatory agent and a regulator of circadian and seasonal
cycles. The amphiphilic character of melatonin enables it to
readily cross the BBB, where in the CNS melatonin receptors
are widely distributed (Yeleswaram et al., 1997; Chen et al.,
2006). Moreover, melatonin has a broad interacting profiles
with intracellular proteins including nuclear receptor ROR/RZR,
quinone reductase 2 (MT3), and calmodulin (Benitez-King
et al., 1993; Cutando et al., 2014). The biological activities of
melatonin cannot be attributed to single pathway or receptor;
but many targets are involved including transduction pathways.
Thus, receptor-dependent and independent actions of melatonin,
its low toxicity profile, and clinical safety records make it
ideal candidate as neuroprotective agent. In renal ischemia,
melatonin exerts nephroprotective effects by attenuating NF-k B
signaling cascade (Li et al., 2009). In cardiac ischemia, melatonin
attenuated oxidative stress by SIRT dependent pathway (Zhai
et al., 2017). In this context, the beneficial effects of this
indolamine in brain ischemia have been recently reviewed
(Ramos et al., 2017). In brain ischemia, several signaling
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EXPERIMENTAL PROCEDURES
Animals Grouping and Drug Treatment
Adult male Sprague–Dawley rats weighing 200–230g (8–9 weeks)
were purchased from Guangdong medical laboratory animal
center, China. The experimental animals were housed at
Laboratory Animal Research Center, Peking University Shenzhen
Graduate School, under 12 h light/12 h dark cycle at 18–22◦ C
and had free access to diet and tap water throughout the study.
The experimental procedures were set in such a way to minimize
rats suffering. All experimental procedures were carried out
according to the protocols approved by Institutional Animal Care
and Use Committee of Peking University Shenzhen Graduate
School. The rats were randomly divided into 4 groups, each group
containing 14 rats: Sham operated control group/Sham; Rats
undergoing permanent middle cerebral artery occlusion/MCAO;
Melatonin treatment to rats undergoing permanent middle
cerebral artery occlusion/Mela+ MCAO; Melatonin treatment to
sham operated group/Mela + Sham.
Single dose of melatonin (5 mg/kg, Sigma, St. Louis, MO,
United States) or vehicle were administered intraperitoneally
30 min before ischemia. This dose of melatonin showed
maximum neuroprotective effects in brain ischemia based upon
dose–response studies of melatonin in focal cerebral ischemia
(Andrabi et al., 2015). Overall 6 rats died during experimental
procedures, three from MCAO, two from Mela+MCAO and one
from sham group.

MCAO Surgery
Middle cerebral artery occlusion was operated as previously
described method (Shah et al., 2014, 2016; Sung et al., 2016).
Briefly, rats were anesthetized by mixture of xylazine and
ketamine (1:3.2, I/P). The right common carotid artery, external
carotid artery, and internal carotid artery were exposed through
a midline cervical incision. The occipital artery, superior thyroid
arteries were knotted with (6/0) silk and subsequently cut. The
external carotid artery was knotted and a nylon filament (3/0)
with blunted rounded tip about 30 mm in length was inserted
from the external carotid artery into internal carotid artery and
advanced further into the origin of the middle cerebral artery,
whereby some resistance to the movement of nylon occurred. The
sham operated animals were subjected to the same procedures
except the insertion of filament. 24 h after the onset of permanent
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occlusion, animals were decapitated with chloroform, and brain
tissues were collected. The major limitation associated with
this model is subarachnoid hemorrhage due to vessel rupturing
and hyperthermia.

and anti-β-Actin (SC-130656) from (Santa Cruz, Biotechnology,
CA, United States). Anti-p-CRMP2 Thr 514 (Cat#9397) and
anti-p- GluR1serine 845 (Cat#4511), was obtained from CST and
were used at dilution of 1:1000.

Neurobehavioral Test

Tissue Collection for Morphology

Twenty eight-point composite neuroscore was used to evaluate
the sensorimotor deficits based on a number of tests including
(1) circling, (2) motility, (3) general condition, (4) righting reflex
when placed on its back, (5) paw placement on table top, (6)
ability to pull itself up on a horizontal bar, (7) climbing on
an inclined platform, (8) grip strength, (9) contralateral reflex,
(10) contralateral rotation when held by the base of its tail, and
(11) visual forepaw reaching. A cumulative score of 28 indicated
healthy functioning while 0 for severe neurological impairment.

We used (n = 7 rats/group)
after collection form different
in 4% paraformaldehyde. The
paraffin, and 4 µm coronary
rotary microtome.

Cresyl Violet Staining
Tissue sections on coated slides were de-paraffinized with three
treatments of absolute xylene and rehydrated with graded ethyl
alcohol. The slides were rinsed with distilled water and immersed
in 0.01 M PBS for 10 min. 0.5% (w/v) cresyl violet acetate (Sigma)
was dissolved in distilled water, and a few drops of glacial acetic
acid were added to the solution just before use. Brain sections
were stained with cresyl violet solution for approximately 20 min.
The slides were rinsed with distilled water and differentiated in
ethyl alcohol (70, 95, and 100%). The slides were cleared with
xylene and were mounted with glass cover slip. The stained
images were pictured with light microscope (Olympus, Japan),
using 20× magnification scale, saved as TIF files and analyzed
by ImageJ, computer based program. The number of images
per slide was five per group. The TIF images was optimized
to the same threshold intensity for all groups for pyknotic, red
and ghost neurons.

TTC Staining
Rats after permanent occlusion were decapitated under
anesthesia at the end of 24 h period. Brain tissue were carefully
removed and washed with cold PBS. 3–4 mm-thick coronary
sections were cut by using sharp blade from frontal lobe. These
coronal slices were incubated in 2% 2,3,5-triphenyltetrazolium
chloride (TTC) (solution was prepared in PBS) for 10–20 min,
until a thorough demarcation was observed for MCAO operated
rats, while sham operated rats were stained deep red (Shah
et al., 2018a). The coronal sections were then fixed in 4%
paraformaldehyde and photographed. The % infarct area was
then measured by utilizing ImageJ, computer based program.
To compensate for brain edema, the corrected brain infarction
was calculated as fallow: Corrected infarct area = left hemisphere
area – (right hemisphere area – infarct area).

Tunel Staining
Tunnel staining was performed according to manufacturer’s
protocol the DNA Fragmentation Detection Kit (Oncogene
Research Products, Cambridge, MA, United States). The deparaffinized sections were permeated with proteinase K followed
by inactivation of peroxidases. The slides were incubated
subsequently in equilibration buffer and with TdT labeling
reaction mixture at 37◦ C for 1.5 h. This reaction was
stopped by stopper buffer. The sections were washed with
PBS and stained in DAB solution, washed with distilled
water, dehydrated in graded ethanol (70, 95, and 100%),
and fixed in xylene and cover-slipped by mounting medium.
Immunohistochemical TIF images were captured with a
light microscope, using 20x magnification scale taking five
images per slide. ImageJ software was used to quantitatively
determine TUNEL positive cells in the frontal cortex and
striatum areas. Briefly, TIF images was optimized to the
same threshold intensity for all groups and was expressed as
the relative TUNEL neuronal cells/ section of the samples
relative to the control.

Western Blot
For the Western blot analysis, the samples were dissolved in
lysis buffer containing (1M Tris–HCI, 5M sodium chloride, 0.5%
sodium deoxycholate, 10% sodium dodecyl sulfate, 1% sodium
azide, 10% NP-40) as described previously (Shah et al., 2014)
The homogenate was sonicated and centrifuged at 15,000 rpm
for 20 min at 4◦ C and protein concentration was determined
by BCA kit (Pierce, Rockford, IL, United States) according
to the guidelines provided by manufacturer. Equal amount of
protein i.e., (30 µg per sample) were electrophoresed on 10%
SDS-PAGE gels followed by immunoblotting for transferring
the protein to PVDF membranes (Millipore, Billerica, MA,
United States). To minimize the non-specific antibody binding,
the PVDF was blocked with skim milk for 1 h at room
temperature. PVDF was washed in TBST and then incubated
with primary antibodies overnight at 4◦ C. The membranes were
then incubated with appropriate secondary antibody, and protein
band were detected using an ECL detection reagent according to
the manufacturer’s instructions (Amersham Pharmacia Biotech,
Piscataway, NJ, United States).
The antibodies used include anti-NR2a (SC-1468), antiPSD95 (SC-71933), anti-GluR1 (SC-55509), anti-SNAP25
(SC-7538), anti-synaptophysin (SC-17750), anti-γ-enolase
(SC-71046), anti-Ppi3k (SC-293115), Anti-CRMP2 (SC-376739),
anti-p-AKT Ser473 (SC-7985), anti-p-GSK3β Ser9 (SC-11757),
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for tissue analysis. The brain
experimental groups was fixed
brains were then imbedded in
sections were made by using

Immunofluorescence Analysis
After de-paraffinization of sections, the slides were autoclaved
in 0.1M sodium citrate pH 6 for antigen retrieval step. The
slides were allowed to cool and washed with PBS twice
times. Slides were incubated with 5% normal serum depending
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was expressed as the relative integrated density of the samples
relative to the control.

upon the source of secondary antibody used. The slides
were incubated with primary antibodies at 4◦ C overnight
(PSD95, NR2a, synaptophysin, γ-enolase, p-PI3K) from Santa
Cruz Biotechnology, and rabbit monoclonal CRMP2, from
cell signaling overnight at 1:100 dilution. Next morning, after
washing with PBS, fluorescent labeled secondary antibodies
(Santa Cruz Biotechnology) were used for signal amplification
in dark chamber, followed by mounted with UltraCruz
mounting medium (Santa Cruz Biotechnology). The slides
were pictured with Confocal scanning microscopes (Flouview
FV 1000, Olympus, Japan) using 40× magnification scale,
and analyzed by ImageJ, computer based program. ImageJ
software was used to quantitatively determine fluorescence
intensity of the same region (frontal cortex and striatum) for
all groups by optimizing background of image according to
the threshold intensity and analyzes the immunofluorescence
intensity at the same threshold intensity for all groups and

Statistical Analysis
Western blot bands and morphological data was analyzed
using ImageJ software (Image J 1.301 ). Data were presented as
means ± SEM. Data were analyzed by two ways ANOVA followed
by post hoc Bonferroni Multiple Comparison test using graphpad prism-5 software. Moreover, TTC staining and neurological
deficit scores were analyzed by Student’s t test. Symbols ∗ or #
represent significant difference values p < 0.05, ∗∗ or ## represent
p < 0.01 and ∗∗∗ or ### represent p < 0.001 values for significant
differences. Symbols ∗ shows significant difference relative to
Sham, while # shows significant difference relative to MCAO.
1

https://imagej.nih.gov/ij/

FIGURE 1 | Effect of melatonin on neurological scores, brain infarction and neurodegeneration. (A) Effect of melatonin on Nissl staining. Representative
photomicrograph of cresyl staining showing the extent of surviving neurons in cortex and striatum; (n = 7 animals/group). The number of experiments performed = 3
and data presented is relative to sham. Magnification 20×, scale bar = 50 µm. (B) Tunel histochemistry with representative photos showed apoptotic cells (scale
bar = 50 µm, magnification 20×). Images are representative of experiments performed 3 times with n = 7 per group. MCAO causes significant neuronal apoptosis;
while treatment with melatonin attenuated apoptotic damage. (C) Brain coronal sections were stained with TTC, which distinguishes between ischemic and
non-ischemic areas. Student’s t-test was used for analysis, (n = 7/group. ∗∗∗ indicates p < 0.001, while symbols ∗∗ and ## represent p < 0.01 significantly different;
# indicates p < 0.05. Symbols ∗ shows significant difference relative to sham control while # shows significant difference relative to MCAO. (D) Coronal sections
separated by frontal cortex (1), parietal cortex and insular cortex (2), and periform cortex (3). The analyzed region of interests indicated by square 1 and F. (E) 28
points composite scoring. Mela+MCAO rats had significantly less severe neurological deficits (# p < 0.05) than MCAO rats had. Mann-Whitney (non-parametric test)
is applied and neurological score data is presented as the median and range (n = 10–14/group).
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FIGURE 2 | Effect of melatonin on glutamate (Glu) receptor subunits. (A) Western blot analysis of NR2a, PSD95, GluR1, p-GluR1 (Serine 845), CRMP2, p-CRMP2
(Thr 514) from sham-operated control group, vehicle-treated MCAO, melatonin-treated MCAO animals and melatonin treated sham group (n = 7 rats per group). The
bands were quantified using ImageJ, analyzed by graph-pad prism-5 software. β-actin was used as control. Densitometric analysis was expressed in arbitrary units
as the mean ± SEM for the indicated proteins. (B) Immunofluorescence reactivity of PSD95 and NR2a; (n = 7 rats/group). The above data is representation of 3
numbers of experiments. Scale bar = 100 µm and magnification 40×. PSD95 and NR2a show cytoplasmic localization and was visualized by FITC and TRITC.
(C) Double immunofluorescence of NR2a and PSD95 in ischemic brain. PSD95 was visualized by FITC and NR2a by TRITC. Scale bar = 20 µm and magnification
40×. (D) Immunofluorescence reactivity of CRMP2; (n = 7 rats/group). The above data is representation of 3 numbers of experiments. Scale bar = 50 µm. CRMP2
was visualized by Alexa-Flour 594. Symbols # represent significant difference values p < 0.05, while symbol ## represent p < 0.01 values for significant differences,
symbol ∗∗∗ and ### shows p < 0.001. Symbols ∗ shows significant difference relative to sham control while # shows significant difference relative to MCAO.

bodies, a phenomenon that could be significantly decreased by
melatonin treatment (Figure 1B). Further calculations of the
corrected percent infarcted area in MCAO and Mela+MCAO
were about to be 45.92 ± 4.3% and 28.71 ± 3.9% (Figure 1C).
Neurological scores were determined 24 h after the onset of
permanent MCAO. Rats subjected to MCAO exhibited severe
neurological deficits. Further analysis of 28 points composite
scoring indicated that sensorimotor functions were hampered in
MCAO rats (Figure 1E), which was tremendously reversed by
melatonin treatment (Figure 1E).

RESULTS
Effect of Melatonin on Ischemic Induced
Neurodegeneration and Apoptosis
During MCAO, robust neuronal changes occurred more
frequently in the core brain where impaired blood supply
caused irreversible cell death. Nissl staining was performed in
frontal cortex and striatum areas to examine the neuroprotective
effects of melatonin and to differentiate necrotic neurons from
intact ones. Compared to sham operated animals, a substantial
difference was observed after 24 h of permanent ischemia, which
showed aberrant morphological features, such as alteration in
neuronal size and shape (swelling and scalloped angular nature),
alteration in color staining (cytoplasmic eosinophilia/pyknosis
and basophilic nature of nucleus) and vacuolation (Figure 1A).
A significant larger number of morphological intact cells could
be found in melatonin treated groups (Figure 1A).
Neuronal apoptosis could be seen after MCAO in the ischemic
penumbra or peri-infarct zone, where blood flow is less severely
reduced. Tunel staining was performed in the frontal cortex and
striatum areas to examine the neuroprotective role of melatonin
on cell apoptosis. As expected, a significant number of Tunelpositive cells was observed in the infarcted neocortex and caudate
putamen of striatum in MCAO rats (Figures 1B,D), which are
compactly stained and accompanied with fragmented apoptotic

Frontiers in Pharmacology | www.frontiersin.org

Effect of Melatonin on Glutamatergic
Receptors Following Permanent MCAO
Accumulated evidences suggested that NMDAR mediated
excitotoxicity accounted for the delayed and progressive neuronal
damage following ischemia. The underlying molecular and
cellular mechanisms remained the center for stroke research
in the last decade (Hoyte et al., 2004; Martin and Wang,
2010; Wu and Tymianski, 2018). Synaptic Glu activity mainly
activated NR2a-containing NMDAR, leading to the activation
of pro- survival signaling proteins including Akt, ERK, and
CREB (Thomas and Huganir, 2004; Terasaki et al., 2010). We,
therefore, studied the expression of NR2a subunit following
permanent MCAO and the effect of melatonin treatment.
Our results showed that full length NR2a protein level was
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FIGURE 3 | Melatonin protects synaptic protein from ischemic injury. (A) Western blot analysis of SNAP-25 and synaptophysin from ischemic cortex and striatum of
vehicle-treated MCAO, melatonin-treated MCAO animals, sham-operated control group, and melatonin treated sham group (n = 7 rats per group). The bands were
quantified using ImageJ, analyzed by graph-pad prism-5 software. β-actin was used as control. Densitometric analysis was expressed in arbitrary units as the
mean ± SEM for the indicated proteins. (B) Immunofluorescence reactivity of synaptophysin; (n = 7 rats/group). The above data is representation of 3 numbers of
experiments. Scale bar = 100 µm and magnification 40×. Synaptophysin was visualized by Alexa-Flour 594. Symbols ∗ or # represent significant difference values
p < 0.05, while symbols ∗∗ and ## represent p < 0.01 values for significant differences, symbol ∗∗∗ shows p < 0.001. Symbols ∗ shows significant difference relative
to sham control while # shows significant difference relative to MCAO.

may exert its neuroprotective effects by attenuated the cleavage of
full length NR2a.
CRMP2 displayed proteolytic cleavage after MCAO. Previous
studies demonstrated close association of NMDA receptor with
CRMP2 (Al-Hallaq et al., 2007) because such mechanisms
regulate the trafficking, expression and internalization of
NMDAR receptor. We then examined the potential effects of
CRMP2 on melatonin treatment. As shown in (Figure 2A)
CRMP2 exhibited a migration pattern of cleaved bands
(Figure 2A), with the intact mass of CRMP2 at 66kD degrading
to 62 and 55kD protein in MCAO group (Zhang et al.,
2007). Melatonin treatment attenuated this cleavage. Similarly,
immunofluorescence results further validated the expression of
these CRMP2 protein (p < 0.001, Figure 2D). Moreover, the
phosphorylated form of CRMP2 (CRMP2 Thr514) also showed
higher expression in MCAO (Figure 2A, p < 0.001).
AMPA receptor activation is triggered by Glu accumulation
following cerebral ischemia. In line with previous reports, we
observed a significantly reduced expression of AMPAR (GluR-1)
receptor following cerebral ischemia (Figure 2A) compare to
sham operated group. Melatonin treatment reversed the effect
of ischemia on AMPA receptors (Figure 2A). Similarly, the
phosphorylation levels of AMPA (GluR1) at serine 845 were
studied and the results showed a marked decrease following

significantly decreased in ischemic conditions as compared
to sham operated group (Figure 2A), while the expression
changes could be reversed on melatonin treatment both in
cortex and striatum, respectively (Figure 2A). The above results
were further confirmed using immunofluorescent staining,
which revealed NR2a immunostaining dramatically decreased
in MCAO operated group (Figure 2B), whereas a strong
NR2a immunoreactivity was observed in cortex and striatum of
Mela+MCAO group (Figure 2B). These results further support
the previous observations, in which MCAO induced decreased
expression of NR2a is implicated with reduced downward
signaling cascade (Chen et al., 2008; Gascon et al., 2008;
Yuen et al., 2008).
Calpain activation leads to the degradation and decreased
expression of full length NR2a in MCAO (Gascon et al., 2008;
Yuen et al., 2008) an effect that could be attenuated by increased
interaction of PSD95/NR2a. We then investigated whether
melatonin affected PSD95/NR2a interaction. Similar expression
patterns of PSD95 and NR2a were found in cortex across
treatment groups (Figures 2A,B), and their co-localization could
be defined in sham operated animals (Figure 2C). However, this
interaction was tremendously reduced in the ischemic brain,
showing parallel decrease of both PSD95 and NR2a in cortex
(Figures 2A–C). Together, these results suggested that melatonin
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FIGURE 4 | Melatonin induces neuroprotection via PI3K/AKT/GSK-3β/CRMP2 pathway. (A) Western blot analysis of γ–enolase, p-PI3K, p-Akt, Akt, p-GSK-3β,
GSK-3β, CRMP2, p-CRMP2 from cortical, and striatal tissues (n = 7 rats/group). The bands were quantified using ImageJ, analyzed by graph-pad prism-5 software.
β-actin was used as control. Densitometric analysis was expressed in arbitrary units as the mean ± SEM for the indicated proteins. (B) Immunofluorescence
reactivity of γ-enolase and p-PI3K; (n = 7 rats/group). The above data is representation of 3 numbers of experiments. Scale bar = 100 µm and magnification 40× (A)
γ-enolase (B) p-PI3K show cytoplasmic localization and was visualized by TRITC and FITC. (C) Double immunofluorescence of γ-enolase and p-PI3K in ischemic
brain. The cortical and subcortical sections show correspondingly decreased expression of γ-enolase and p-PI3K after 24 h of permanent ischemia. γ-enolase
visualized by TRITC and p-PI3K was by FITC. Symbol # represent significant difference values p < 0.05, while symbols ∗∗ and ## represent p < 0.01 values for
significant differences, symbol ∗∗∗ shows p < 0.001. Symbol ∗ shows significant difference relative to sham control while # shows significant difference relative
to MCAO.

effect of melatonin on these neuronal survival and regenerative
related molecules, we performed western blot analysis. Our
results showed that γ-enolase expression decreased during
brain ischemia, and melatonin treatment recovered the
protein expression level (Figures 4A,B). Moreover, a strong
immunoreactivity was noticed in cortex and striatum
of sham operated group and Mela + MCAO operated
group for γ-enolase and p-PI3K (Figures 4A,B), while this
immunostaining dramatically decreased in MCAO operated
group (Figure 4B). γ-enolase and p-PI3K were co-localized by
double immunofluorescence (Figure 4C). Together, these results
demonstrated that melatonin might exert its neuroprotective
effects via increasing γ-enolase/PI3K/Akt pathway, with Akt at
serine 473 working as survival kinases which prevent apoptosis
by phosphorylating its downstream target glycogen synthase
kinase-3β (GSK-3β at serine 9).

MCAO, as compared to sham operated control (Figure 2A).
Melatonin treatment significantly reversed the changes in the
p-AMPA in cortical and striatal tissues (Figure 2A).

Melatonin Prevents Synaptic Dysfunction
by Preserving Synaptic Protein Following
Cerebral Ischemia
Synaptic plasticity and synaptogenesis are highly desirable
cellular processes for functional restoration after ischemic stroke.
It has been demonstrated that SNAP-25, and synaptophysin
acts as synaptic marker for neuronal differentiation (Bailey
and Lahiri, 2006; Goddard et al., 2008). To examine the
neuroprotective effect of melatonin on synaptic proteins
following cerebral ischemia, the expression of synaptophysin, and
SNAP-25 were studied. The results showed that synaptophysin
and SNAP-25 expression were significantly decreased in MCAO
groups, while melatonin treatment reversed the deleterious effect
on these proteins (Figure 3A). Moreover, immunofluorescence
showed a strong synaptophysin immunoreactivity in the cortex
and striatum of the sham operated control group, which
was considerably diminished following 24 h after MCAO but
recovered in melatonin treated group (Figure 3B).

DISCUSSION
In the present study, we have demonstrated that melatonin
attenuates MCAO-induced apoptosis and neurodegeneration
both in cortical and striatal tissue. The extent of injury caused
by MCAO depends upon the duration of occlusion. The
permanent MCAO produces the most uniform type of infarction
which frequently involves the neocortex and striatum (Popp
et al., 2009). Blood flow to striatum is lower than cortex;
due to which striatum is severely hit by ischemic stroke (Lo
et al., 2003). This is because blood supply to the striatum is
provided by tiny unidirectional vessels from MCA and there
is no collateral connection to this area form surrounding
vasculature (Fluri et al., 2015). Our study showed that
melatonin treatment protected NR2A from ischemic cleavage via

Melatonin Promote
γ-Enolase/PI3K/AKT/GSK-3β/CRMP2
Pathway
Apart from its effects on NR2a expression and NR2a/PSD95
interaction, melatonin can promote a variety of neurotrophic
factors. Previous reports demonstrated that γ-enolase enhances
neuronal survival, differentiation, and neurite regeneration
via activating the PI3K/Akt and other related signaling
pathways (Hafner et al., 2012). To examine the potential
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shown here that 24 h of cerebral ischemia down regulated
NR2a and melatonin treatment counteract this proteolysis.
Furthermore, NR2a is protected from calpain degradation by
PSD95 shielding. In cortex, we observed down regulation of
PSD95 which might expose NR2a to calpain mediated cleavage,
whereas melatonin treatment restored PSD95 expression and
maintained the protective interaction of PSD95 with NR2a.
AMPA receptor subunits (GluR1, GluR2, GluR3, and GluR4)
also play a vital role in Glu induced excitotoxicity. AMPA
receptor activity is controlled by several mechanisms including
phosphorylation and calpain mediated cleavage of GluR1 subunit
(Yuen et al., 2007). In line with previous reports we observed
down regulation of GluR1 in ischemic cortex and striatum in
our ischemic model. Phosphorylation at serine 845 is involved
in the translocation of AMPA to neuronal membrane (Esteban
et al., 2003). Such AMPAR actions boost synaptic plasticity for
learning and memory. Our results that melatonin treatment
recovered GluR1 serine 845 phosphorylation could increase and
stabilize AMPAR membrane surface expression, which could
possibly be the underling neuroprotective mechanism in memory
impairment model.
Ischemic stroke rigorously disrupts synaptic networks, while
some reports suggested synaptic remolding after ischemic
damage with correspondingly increased synapse formation
(Hammond et al., 1994; Jourdain et al., 2002). Synaptophysin

increasing its coupling to PSD95, which further promoted NR2A
mediated pro-survival signaling of γ-enolase/pI3K/Akt/GSK3β/
CRMP2 pathway. Finally, we also demonstrated synaptoprotective effect of melatonin and suggested that melatonin
attenuates MCAO induced oxidative stress possibly by preserving
synaptic structure of protein. Moreover, stroke therapy academy
industrial roundtable (STAIR) recommends neuroprotective
agents should protect gray and white matter from ischemic
torment (Fisher et al., 2009).
The role of NMDA subunits in ischemic brain injury
is intensively debated due to contradicting results. Previous
results pointed out the major shortfalls accompanied with
Glu antagonism which showed repetitive clinical trial failures
(Ikonomidou and Turski, 2002; Hoyte et al., 2004). It is coequally
believed that NR2a subunit of NMDA has pro survival while
NR2b is linked to neuronal apoptosis irrespective of synaptic
location (Liu et al., 2007; Chen et al., 2008). Further reports
suggested potential therapeutics mechanisms by selectively
targeting proteins implicated in trafficking, expression and
internalization of NMDAR receptor, without altering the intrinsic
properties of receptor (Kemp and McKernan, 2002). Calpain is
activated by ischemic injury, which degrades a large array of
molecules including NMDA receptor subunits and are implicated
in the pathogenesis of MCAO ( Kemp and McKernan, 2002;
Simpkins et al., 2003). In agreement to previous reports, we

FIGURE 5 | Proposed schematic presentation of melatonin in MCAO stroke. A schematic diagram of suggested neuroprotective mechanism of melatonin in MCAO
stroke brain. This diagram shows the possible mechanism by which melatonin prevent MCAO-induced neuronal damage, synaptic deficit, and neurodegeneration
through Enolase/PI3K/AKT/CRMP2 pathway.
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and SNAP-25 level was compromised in ischemic brain injury
compare to melatonin treated groups. Moreover, PSD95 showed
hyper expression in permanent ischemic injury for reasons
explained previously (Martone et al., 1999; Hu et al., 2000;
Kovalenko et al., 2006). Both PSD95 and synaptophysin,
promotes synaptic plasticity, and synaptogenesis. Moreover,
some studies demonstrated altered expression of PSD95 to
cognitive impairment (Yan et al., 2013). The expressions
of both these proteins are markedly attenuated in ischemic
cortex and melatonin treatment rescue these proteins from
ischemic torment.
Impairment of the PI3K/Akt signaling pathway is
implicated in major neurodegenerative diseases including
ischemic stroke. γ-enolase, also called neuronal specific
enolases (NSE), an important molecule to directly assesses
neuronal damage and repair, has been shown to control
neuronal survival, differentiation, and neurite regeneration by
activating the PI3K/Akt and MAPK/ERK signaling pathways
(Lee et al., 2004, 2005). γ-enolase mediated PI3K activation, also
regulates RhoA kinase, a key regulator of actin cytoskeleton
organization, and may influence both neurodegeneration
and neuroprotection depending on the signal strength. Our
results showed attenuated expression of γ-enolase and PI3K
in ischemic brain, whereas melatonin treatment enhanced
γ-enolase/PI3K/Akt signaling pathway, suggesting the prosurvival signaling possibly involving NR2a. These results are in
agreement with previous reported studies (Shehadah et al., 2010;
Gim et al., 2015).
CRMP2 is associated with axonal growth as it adds essential
microtubule filaments. The biological role of CRMP2 and
its phosphorylated form CRMP2 (Thr514) in ischemic brain
injury remained unknown. Contradicting reports exist with
some studies suggesting hyper-expression of CRMP2 (Indraswari
et al., 2009; Shah et al., 2014) while others observed attenuated
expression in ischemic brain injury. During brain injury, CRMP2
(66 kDa) was degraded into 55 kDa BDP by calpain mediated
proteolysis (Yoshimura et al., 2005; Yang et al., 2016). Distinct
from the previous reports of reduced p-CRMP2 expression in
neonatal 6-h focal hypoxic ischemic model (Sato et al., 2011; Yang
et al., 2016), our results of higher expression of p-CRMP2 are
in according with the increased activity of GSK-3β and can be
reversed by phosphorylating GSK-3β at Ser-9. Indeed, melatonin
restores the expression of PI3-kinase and inactivates Akt via
phosphorylating the sites at Thr-308 and Ser-473. This leads
to GSK-3β inactivation via Ser-9 phosphorylation, supporting
previous results that GSK3-β is negative regulator of axonal
growth by modulating CRMP2 activity (Yoshimura et al., 2005;
Gim et al., 2013). Thus, melatonin preserved the integrity of
CRMP2 and ameliorated the neuropathological changes elicited

via CRMP2 phosphorylation at Thr 514 (Takata et al., 2009;
Gim et al., 2013). Finally, we have also observed consistent
increase in the expression of synaptophysin (axonal marker)
by melatonin, which further suggests the protective effect of
melatonin on axonal growth.
In conclusion, our results demonstrated that melatonin
modulated ischemic injury-induced glutamatergic impairment,
synaptic dysfunction, apoptotic marker, and neurodegeneration
in ischemic brain. We have shown for the first time (as per our
information and literature survey) the aberrant expression of
NMDA and AMPA glutamatergic receptor in striatum. Notably,
treating rats with melatonin augmented the neurotrophic activity
of enolase, which produces neuroprotection by downstream
targets (pI3K/Akt/GSK3β/CRMP2). The suggested mechanistic
approach of melatonin in MCAO-induced model to attenuate
synaptic dysfunction and to mediate NR2a dependent survival
pathway is summarized in Figure 5.
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